The benefits of tamoxifen as primary prevention of breast cancer are well established. The good news is that the benefits live on, with a protective effect that extends up to 22 years. At a median follow-up of 16 years, women treated with 5 years of tamoxifen enjoyed a 29% reduction in the risk of developing any type of breast cancer and a 35% reduction in the risk of developing estrogen receptor–positive breast cancer compared with placebo-treated controls. These positive results of the large International Breast Cancer Intervention Study (IBIS-I) were presented at the 2014 San Antonio Breast Cancer Symposium and published online simultaneously in “Tamoxifen is a well-established and effective treatment for certain breast cancers, but now we have evidence of its very long-term preventive benefits in women at risk for breast cancer. The preventive effect of tamoxifen is highly significant, with a reduction in breast cancer rates of around one-third, and this impact has remained strong and unabated for 20 years. We hope these results will stimulate more women, particularly younger women, to consider treatment options for breast cancer prevention if they have a family history of the disease or other risk factors,” stated lead author Jack Cuzick, Ph D, of Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, United Kingdom. Even though these long-term results are so striking, Dr. buy propranolol uk online 'Breast cancer deaths halved if patients given "wonder drug" tamoxifen for 10 years, not five,' reports the Daily Mail. This headline is based on a study of the effectiveness and side effects of extended tamoxifen treatment in women with early-stage oestrogen-sensitive breast cancer. As the name suggests, oestrogen-sensitive (ER) breast cancers are growths of cancerous cells that are stimulated by the hormone oestrogen. Tamoxifen is used to block the effects of oestrogen on these ER cancers. Tamoxifen is commonly offered alongside other breast cancer treatments and it is usually recommended that treatment with the drug continues for five years after other treatments have ended. This is because research has found that a long-term course of tamoxifen can reduce the risk of breast cancer returning (recurrence) and can also help prevent breast cancer deaths. The researchers thought that extended treatment for 10 years may offer further benefits. Buy clomid online cheap uk Is it legal to buy cytotec online The ASCO clinical practice guideline now recommends treatment with adjuvant tamoxifen for 10 years in women with stage I-III hormone. rxmeds hub order viagra super active online ATLAS randomized 12,894 women between 19 with early breast cancer to continue tamoxifen for 10 years versus stopping at 5. The benefits of tamoxifen as primary prevention of breast cancer are well. At 10 years, previous results of the trial showed that the number. Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with estrogen receptor-positive (ER ) breast cancer. The international ATLAS study showed that 10 years of tamoxifen reduced the risk of dying by 29% during the second decade after diagnosis compared with 5 years of treatment. These findings were presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.“We already knew that 5 years of tamoxifen was very effective and has a carryover effect after stopping, with about a 30% reduction in mortality over the next 5 years. We wanted to do a longer-term treatment trial on tamoxifen to see if we could beat the carryover effect of 5 years of treatment,” said Richard Gray, MSc, Clinical Trial Service Unit, University of Oxford, Oxford, U. Gray presented the results on behalf of lead author Christina Davies, MD, also of the University of Oxford. ATLAS enrolled 6846 women with ER breast cancer between 19. Approximately half the women had node-positive disease, and all had been taking tamoxifen for 5 years. Women were randomized to 5 more years of tamoxifen or no more tamoxifen. After surgery and other treatments (chemotherapy, radiation therapy), women diagnosed with early-stage, hormone-receptor-positive breast cancer usually take 5 years of a hormonal therapy medicine to lower recurrence risk (the cancer coming back). When hormonal therapy is used this way, it's called adjuvant hormonal therapy. Of the adjuvant hormonal therapy choices, tamoxifen has been approved the longest and is approved to treat both premenopausal and postmenopausal women. The other main type of hormonal therapy medicines are the aromatase inhibitors, which are approved to treat only postmenopausal women. While most women take tamoxifen for 5 years, it hasn't been clear if taking tamoxifen for a longer time would offer more benefits. In December 2012, results from the ATLAS study were presented at the San Antonio Breast Cancer Symposium showing that taking tamoxifen for 10 years instead of 5 years after surgery: Now another large study has found similar results: 10 years of tamoxifen is better than 5. The study, "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5,” was presented June 1, 2013 at the 2013 American Society of Clinical Oncology Annual Meeting. Tamoxifen for 10 years Long-term effects of continuing adjuvant tamoxifen to 10 years., Extended Tamoxifen Use in Breast Cancer Is Ten the Magic Number? Best ways to take xanax Should azithromycin be refrigerated Tadalafil usa Where to buy accutane in kuala lumpur Buy viagra alternatives uk The study suggested that taking Tamoxifen for 10 years, instead of stopping after five years, may be beneficial for estrogen-receptor positive. Breaking News from San Antonio Tamoxifen for 10 Years? Young. Tamoxifen Prevention of Breast Cancer Extends More Than 16 Years Ten Years of Tamoxifen Reduces Breast Cancer Recurrences. Studies have already shown that women taking tamoxifen for 10 years have fewer recurrences of their cancer than those on the drug for five. is valacyclovir safe during pregnancy In December 2012, results from the ATLAS study were presented at the San Antonio Breast Cancer Symposium showing that taking tamoxifen. Showed that in oestrogen receptor ER-positive disease, 5 years of tamoxifen is significantly less effective than 10 years in reducing 15-year.